Literature DB >> 7491709

Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency.

F J Gonzalez1, P Fernandez-Salguero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7491709     DOI： 10.1016/s0165-6147(00)89065-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  12 in total

Review 1.  Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.

Authors:  Norman H Lee
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

2.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

Authors:  X Wei; H L McLeod; J McMurrough; F J Gonzalez; P Fernandez-Salguero
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.

Authors:  Suminobu Ito; Takeshi Kawamura; Makoto Inada; Yoshiharu Inoue; Yukihiro Hirao; Toshihisa Koga; Jun-ichi Kunizaki; Takefumi Shimizu; Hitoshi Sato
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 4.  Pharmacogenetics of cancer therapy: getting personal.

Authors:  E Y Krynetski; W E Evans
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

Review 5.  Uridine nucleotide receptors and their ligands: structural, physiological, and pathophysiological aspects, with special emphasis on the nervous system.

Authors:  E Heilbronn; B H Knoblauch; C E Müller
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

6.  Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations.

Authors:  J M Morsman; J Sludden; M M Ameyaw; J Githang'A; A Indalo; D Ofori-Adjei; H L McLeod
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

7.  Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

Authors:  Samar Ismail Hamdy; Masahiro Hiratsuka; Kaori Narahara; Mervat El-Enany; Nadia Moursi; Mohammed Salah-Eldin Ahmed; Michinao Mizugaki
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

Review 8.  How may anticancer chemotherapy with fluorouracil be individualised?

Authors:  Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.

Authors:  S A Ridge; J Sludden; O Brown; L Robertson; X Wei; A Sapone; P M Fernandez-Salguero; F J Gonzalez; P Vreken; A B van Kuilenburg; A H van Gennip; H L McLeod
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 10.  Pharmacogenomics: marshalling the human genome to individualise drug therapy.

Authors:  W E Evans
Journal:  Gut       Date:  2003-05       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.